Table 3.
Multimodal treatment approach during follow-up
| OFTC N = 16 |
FTC N = 46 |
Total N = 62 |
p value | |
|---|---|---|---|---|
| ERT: | 6 | 17 | 24 | 1.0 |
| Neck | 3 | 3 | 6 | |
| Brain | 1 | 1 | 2 | |
| Pleura | 0 | 1 | 1 | |
| Bone | 2 | 13 | 15 | |
| Surgical procedures: | 10 | 17 | 27 | 0.089 |
| Local recurrence | 4 | 5 | 9 | |
| Cervical lymph nodes | 4 | 5 | 9 | |
| Bone metastasis | 2 | 6 | 8 | |
| Atypical lung resection | 3 | 2 | 5 | |
| Chemotherapy | 4 | 4 | 8 | 0.187 |
| Rhenium-186-HEDP | 0 | 1 | 1 | 1.0 |
| DOTA-TATE therapy | 0 | 2 | 2 | 1.0 |
| Redifferentiation | 1 | 9 | 10 | 0.43 |
| TKI | 4 | 7 | 11 | 0.452 |
Thirty-four percent of these patients were treated with ≥ 1 of these treatment options
OFTC Hürthle cell carcinoma, FTC follicular thyroid cancer, ERT external radiation therapy, TKI tyrosine kinase inhibitor